The key receptors targeted by ImmunOs are called LILRB (leukocyte immunoglobulin-like) receptors (also known as immunoglobulin-like transcripts (ILTs)). LILRB receptors control inflammatory responses and cytotoxicity to help regulate the immune response and limit autoreactivity. These receptors transduce a negative signal to immune cells such as macrophages, MDSCs, T, B and NK cells and thereby inhibit stimulation of an immune response. In addition, specific NK receptors (such as KIR3DL1) also regulate immune cell activity. ImmunOs has created a pipeline of therapies that by targeting inhibitory receptors either activate the immune cells to treat cancer or suppress immune cells for inflammatory diseases.
The diagram below illustrates the ability of ImmunOs to design therapies that either dial down the activity of immune cells to treat inflammatory diseases or dial up the immune cell activity to treat cancers.
